



PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3474.1001-001 (formerly NIIN-P01-011)		APPLICATION NO. 10/003,740				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION February 27, 2003 (Use several sheets if necessary)		APPLICANT Mel H. Epstein and Kjesten A. Wiig						
		FILING DATE October 31, 2001		CONFIRMATION NO. 2709	GROUP 1614			
U.S. PATENT DOCUMENTS								
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME				
	AA			<div style="transform: rotate(-15deg); font-weight: bold; font-size: 1.2em;">RECEIVED</div> <div style="transform: rotate(-15deg); font-weight: bold; font-size: 0.8em;">MAR 11 2003</div> <div style="transform: rotate(-15deg); font-weight: bold; font-size: 0.8em;">TECH CENTER 1600/2900</div>				
	AB							
	AC							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	AL							
	AM							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
6	AR2	Kuczenski, R., et al., "Hippocampus Norepinephrine, Caudate Dopamine and Serotonin, and Behavioral Responses to the Stereoisomers of Amphetamine and Methamphetamine," <i>J. of Neuroscience</i> , 15(2):1308-1317 (1995).						
9	AS2	Smith, R.C., et al., "Comparative Effects of d-Amphetamine, l-Amphetamine, and Methylphenidate on Mood in Man," <i>Psychopharmacology</i> 53:1-12 (1977).						
9	AT2	Balster, R.L., et al., "A Comparison of d-Amphetamine, l-Amphetamine, and Methamphetamine Self-administration in Rhesus Monkeys," <i>Pharm. Biochem. and Behavior</i> , 1:67-71 (1973).						
8	AU2	Jelic, V., et al., "Quantitative Electroencephalography in Mild Cognitive Impairment: Longitudinal Changes and Possible Prediction of Alzheimer's Disease," <i>Neurobiology of Aging</i> , 21:533-540 (2000).						
6	AV2	Pepeu, G., "Memory Disorders: Novel Treatments, Clinical Perspective," <i>Life Sciences</i> , 55(25-26): 2189-2194 (1994).						
6	AW2	Bartus, R.T., "Drugs to Treat Age-Related Neurodegenerative Problems," <i>JAGS</i> , 38(6):680-695 (1990).						
EXAMINER				DATE CONSIDERED 9-23-03				

Form PTO/SB/08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
NIIN-P01-011Application Number
10/003,740Applicant
Epstein et al.Filing Date
October 31, 2001Group Art Unit
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS


(Including Author, Title, Date, Pertinent Pages Etc.)

6	DB	Blaug, S.M. & Huang, W.-T. Interaction of Dextroamphetamine Sulfate with Spray-Dried Lactose. <i>J. Pharmaceutical Sciences</i> 61, 1770-1775 (Nov. 1972).
6	DC	Brown, R.W. et al. D-amphetamine facilitation of Morris water task performance is blocked by eticlopride and correlated with increased dopamine synthesis in the prefrontal cortex. <i>Behavioural Brain Res.</i> 114, 135-143 (2000).
6	DD	Carr, G.D. & White, N.M. The relationship between stereotypy and memory improvement produced by amphetamine. <i>Psychopharmacology</i> 82, 203-209 (1984).
6	DE	Corsi-Cabrera, M. et al. Gender Differences in the EEG During Cognitive Activity. <i>Intern. J. Neurosci.</i> 72, 257-264 (1993).
6	DF	Ebert, U. & Kirch, W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. <i>Euro. J. Clin. Invest.</i> 28, 944-949 (1998).
6	DG	Finkelstein, J.E. et al. Milacemide Treatment in Mice Enhances Acquisition of a Morris-Type Water Maze Task. <i>Pharmacol. Biochem. & Behav.</i> 49, 707-710 (1994).
6	DH	Harris, H. et al. Behavioral Properties of Amphetaminil Enantiomers. <i>NCDEU Meeting</i>
6	DI	Jonason, K.R. et al. Effects of Amphetamine Upon Relearning Pattern and Black-White Discriminations Following Neocortical Lesions in Rats. <i>J. Comparative & Physiological Psychology</i> 73, 47-55 (1970).
6	DJ	Kikuchi, M. et al. EEG Changes following Scopolamine Administration in Healthy Subjects. <i>Neuropsychobiology</i> 39, 219-226 (1999).
6	DK	Kumar, V. & Banker, G.S. Maillard Reaction and Drug Stability. <u>Maillard Reactions in Chemistry, Food, and Health.</u> Theodore P. Labuza et al., eds. The Royal Society of Chemistry (1994).
6	DL	Martinez, J.L. et al. Central and Peripheral Actions of Amphetamine on Memory Storage. <i>Brain Res.</i> 182, 157-166 (1980).

Form PTO/SB/08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
NIIN-P01-011Application Number
10/003,740Applicant
Epstein et al.Filing Date
October 31, 2001Group Art Unit
1614Monmaur, P. et al. Involvement of Septal Muscarinic Receptors in Cholinergically Mediated Changes in Rat Rearing Activity. *Pharmacol. Biochem. & Behav.* 58, 577-582 (1997).Nickel, B. et al. Effect of Enantiomers of Deprenyl (Selegiline) and Amphetamine on Physical Abuse Liability and Cortical Electrical Activity in Rats. *Neuropharmacology* 29, 983-992 (1990).

DO

Pitsikas, N. et al. DAU 6215, A Novel 5-HT₃ Receptor Antagonist, Improves Performance in the Aged Rat in the Morris Water Maze Task. *Neurobiol. Aging* 14, 561-564 (1993).

DP

Pitsikas, N. et al. Effect of Org2766, an ACTH(4-9) Analogue, on Recovery After Bilateral Transection of the Fimbria Fornix in the Rat. *Pharmacology, Biochem. & Behav.* 38, 931-934 (1991).

DQ

Ramos, J. et al. EEG Activity During Cognitive Performance in Women. *Intern. J. Neurosci.* 69, 185-195 (1993).

DR

Riekkinen, P. Jr. Effects of Alzene and tacrine on water maze reference and working memory function in medial septal-lesioned rats. *Brain Res.* 714, 118-124 (1996).

DS

Sainsbury, R.S. Hippocampal Theta: a Sensory-inhibition Theory of Function. *Neurosci. & Biobehav. Rev.* 22, 237-241 (1998).

DT

Sarter, M. et al. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. *Psychopharmacology* (Berl). 107, 144-59 (1992).

DU

Sarter, M. et al. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. *Psychopharmacology* (Berl). 107, 461-73 (1992).

DV

Squire, L.R. Cerebral protein synthesis inhibition and discrimination training: effects of D-amphetamine. *Brain Res.* 177, 401-406 (1979).

DW

Van Rijzingen, I.M.S. et al. ACTH(4-9) Analog ORG2766 Treatment 7 Months Delayed Still Improves Morris Maze Performance of Fimbria-Lesioned Rats. *Pharmacol. Biochem. & Behav.* 53, 163-169 (1996).

DX

Yasar, S. et al. Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research. *J. Neural Transmission* [Suppl 48] Springer Verlag Wien, New York (1996).

DY

Young, G.A. Relationship Between Amphetamine-Induced Effects on EEG Power Spectra and Motor Activity in Rats. *Pharmacol. Biochem. & Behav.* 30, 489-492 (1988).

EXAMINER

DATE CONSIDERED

7-25-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900

Form PTO/SB/08	Docket Number (Optional) NIIN-P01-011	Application Number 10/003,740
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Applicant Epstein et al.	
	Filing Date October 31, 2001	Group Art Unit 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
3	AA 2,828,343	3/25/58	Tindall et al.			
4	AB 3,996,381	12/7/76	Florvall et al.			
5	AC 5,075,338	12/24/91	Knoll et al.			
6	AD 5,220,068	6/15/93	Knoll et al.			

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
7	AE GB 2122617 A	1/18/84	United Kingdom				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

8	AF	Angrist & Gershon. Some Recent Studies of Amphetamine Psychosis – Unresolved Issues. 197-203.
9	AG	Axelrod, J. Amphetamine: Metabolism, Physiological Disposition and its Effects on Catecholamine Storage. <u>Amphetamines and Related Compounds</u> <i>Proceedings of the Mario Negri Institute for Pharmacological Res., Milan, Italy.</i> E. Costa & S. Garattini, eds. Raven Press, N.Y. 207-216 (1970).
10	AH	Axelrod, J. The Enzymatic Deamination of Amphetamine (Benzedrine). <i>From the Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Public Health Service, U.S. Dept. of Health, Edu. & Welfare, Bethesda, MD, 753-763</i> (Received for publication, 23 Nov. 1954).
11	AI	Beckett, A.H. et al. Metabolic oxidation on aliphatic basic nitrogen atoms and their α -carbon atoms – some unifying principles. <i>J. Pharm. Pharmac.</i> 23, 809-812 (1971).
12	AJ	Benzeneethanamine, α -methyl-. <i>SciFinder Scholar</i> Registry Number 51-64-9, 2 (15 September 2001).
13	AK	Biel, J.H. Structure-Activity Relationships of Amphetamine and Derivatives. <u>Amphetamines and Related Compounds</u> <i>Proceedings of the Mario Negri Institute for Pharmacological Res., Milan, Italy.</i> E. Costa & S. Garattini, eds. Raven Press, N.Y. 3-19 (1970).
14	AL	Biel, J.H. & Bopp, B.A. Amphetamines: Structure-Activity Relationships. 1, 1-39
15	AM	Browne, R.G. & Segal, D.S. Metabolic and Experiential Factors in the Behavioral Response to Repeated Amphetamine. <i>Pharmacol. Biochem. Behavior</i> 6, 545-552 (1977).
16	AN	Buresova, O. & Bures, J. Radial Maze as a Tool for Assessing the Effect of Drugs on the Working Memory of Rats. <i>Psychopharmacology</i> 77, 268-271 (1982).
17	AO	Clement, B. et al. Reduction of Amphetamine Hydroxylamine and Other Aliphatic Hydroxylamines by Benzamidoxime Reductase and Human Liver Microsomes. <i>Chem. Res. Toxicol.</i> 13, 1037-1045 (2000).

Form PTO/SB/08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
NIIN-P01-011Application Number
10/003,740Applicant
Epstein et al.Filing Date
October 31, 2001Group Art Unit
1614

2

5

8

AT

4

6

7

RECEIVED

TECH CENTER 1600/2900

9

10

AX

11

12

AY

13

14

AZ

15

16

BA

17

18

BB

19

20

BC

21

22

BD

23

24

BE

25

26

BF

27

28

Cochran, J.C. et al. Decoupling Motor Memory Strategies: Effects of Sleep Deprivation and Amphetamine. *Intern. J. Neurosci.* 74, 45-54 (1994).

Cochran, J.C. et al. Parsing Attentional Components During a Simple Reaction Time Task Using Sleep Deprivation and Amphetamine Intervention. *Perceptual and Motor Skills*

Crabbe, J.C. & Alpern, H.P. d-Amphetamine: Disruptive Effects on the Long-Term Store of Memory and Proactive Facilitatory Effects on Learning in Inbred Mice. *Pharmacology Biochem. & Behavior* 3, 647-652 (1975).

Dalla Croce, P. et al. A Simple Procedure for N-Propenylation and N-Propynylation of Secondary Amines.

Davis, J.M. et al. Effects of Urinary pH on Amphetamine Metabolism. *Annals of N.Y. Acad. Sci.* 179, 493-501 (6 July 1971).

Dring, L.G. et al. The fate of amphetamine in man and other mammals. *J. Pharm. Pharmac.* 18, 402-405 (1966).

Dring, L.G. et al. The Metabolic Fate of Amphetamine in Man and other Species. *Biochem. J.* 116, 425-435 (1970).

Fleming, K. et al. Neuropsychological Effects of Amphetamine May Correlate with Personality Characteristics. *Psychopharmacology Bulletin* 31, 357-362 (1995).

Gelowitz, D.L. et al. Chronic L-Deprenyl or L-Amphetamine: Equal Cognitive Enhancement, Unequal MAO Inhibition. *Pharmacol. Biochem. Behav.* 47, 41-45 (1994).

Gibbs, M.E. Effects of Amphetamine on Short-Term, Protein-Independent, Memory in Day-Old Chickens. *Pharmacology Biochem. & Behavior* 4, 305-309 (1976).

Gold, P.E. et al. Modulation of Long-Term Potentiation by Peripherally Administered Amphetamine and Epinephrine. *Brain Res.* 305, 103-107 (1984).

Gunaratna, C. & Kissinger, P.T. Investigation of stereoselective metabolism of amphetamine in rat liver microsomes by microdialysis and liquid chromatography with precolumn chiral derivatization. *J. Chromatography* 828, 95-103 (1998).

Gunne, L.-M. The Urinary Output of d- and l-Amphetamine in Man. *Biochemical Pharmacology* 16, 863-869 (1967).

Haycock, J.W. et al. Effects on Retention of Posttraining Amphetamine Injections in Mice: Interaction with Pretraining Experience. *Psychopharmacology* 54, 21-24 (1977).

Hutchaleelaha, A. et al. Disposition Kinetics of d- and l-Amphetamine Following Intravenous Administration of Racemic Amphetamine to Rats. *Drug Metabolism & Disposition* 22, 406-411 (1994).

Krivanek, J.A. & McGaugh Facilitating Effects of Pre- and Posttrial Amphetamine Administration on Discrimination Learning in Mice. *Agents & Actions* 1, 36-42 (1969).

Law, M.Y.L. et al. Selective Involvement of Cytochrome P450 2D Subfamily in In Vivo 4-Hydroxylation of Amphetamine in Rat. *Drug Metabolism & Disposition* 28, 348-353 (2000).

Form PTO/SB/08

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION



(Use several sheets if necessary)

OCT 04 2002

Docket Number (Optional)
NIIN-P01-011Application Number
10/003,740Applicant
Epstein et al.Filing Date
October 31, 2001Group Art Unit
1614

BG	Law, M.Y.L. & Moody, D.E. Urinary Excretion of Amphetamine and 4'-Hydroxyamphetamine by Sprague Dawley and Dark Agouti Rats. <i>Life Sciences</i> 54, 1073-1079 (1994).
BH	Lee, E.H.Y. & Ma, Y.L. Amphetamine Enhances Memory Retention and Facilitates Norepinephrine Release From the Hippocampus in Rats. <i>Brain Res. Bulletin</i> 37, 411-416 (1995).
BI	Lin, J.S. et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. <i>J. Sleep Res.</i> 9, 89-96 (March 2000).
BJ	Lokiec, F. et al. A Comparison of the Kinetics of d- and l-Amphetamine in the Brain of Isolated and Aggregated Rats. <i>Psychopharmacology</i> 58, 73-77 (1978).
BK	Magidson, O.Y. & Garkusha, G.A. The synthesis of 2-phenylisopropylamine (phenamine). <i>Chemical Abstracts</i> 35, 5868 (1941).
BL	M'Harzi, M. et al. d-Amphetamine Enhances Memory Performance in Rats with Damage to the Fimbria. <i>Physiology & Behavior</i> 42, 575-579 (1988).
BM	Ogata, A. Constitution of ephedrine. <i>Chemical Abstracts</i> 14, 745 (1920).
BN	PDR 946, 1221 (1969).
BO	Penetar, D.M. et al. Amphetamine Effects on Recovery Sleep Following Total Sleep Deprivation. <i>Human Psychopharmacology</i> 6, 319-323 (1991).
BQ	Platel, A. & Porsold, R.D. Habituation of Exploratory Activity in Mice: A Screening Test for Memory Enhancing Drugs. <i>Psychopharmacology</i> 78, 346-352 (1982).
BR	Quartermain, D. & Altman, H.J. Facilitation of retrieval by d-amphetamine following anisomycin-induced amnesia. <i>Physiological Psych.</i> 10, 283-292 (1982).
BS	Quartermain, D. & Jung, H. Persistence of Retrieval Enhancement by Amphetamine Following Scopolamine-Induced Amnesia. <i>Pharmacology Biochem. Behav.</i> 33, 51-54 (1989).
BT	Quartermain, D. et al. Amphetamine Enhances Retrieval Following Diverse Sources of Forgetting. <i>Physiology & Behavior</i> 43, 239-241 (1988).
BU	Richards, J.B. et al. Trained and Amphetamine-Induced Circling Behavior in Lesioned Transplanted Rats. <i>J. Neural Transplant Plast</i> 4, 157-166 (1993).
BV	Richter-Levin, G. & Yaniv, D. Is LTP in the Hippocampus a Useful Model for Learning-Related Alterations in Gene Expression? <i>Rev. Neurosci.</i> 12, 289-296 (2001).
BW	Riviere, G.J. et al. Disposition of Methamphetamine and its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration. <i>J. Pharmacol. Exp. Ther.</i> 292, 1042-1047 (2000).
	Sanders-Bush, E. & Sulser, F. Metabolic and Neurochemical Aspects of the Pharmacology of Amphetamine and Para-Chloroamphetamine. 8, 69-70.

Form PTO/SB/08		Docket Number (Optional) NIIN-P01-011		Application Number 10/003,740	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Epstein et al.			
		Filing Date October 31, 2001		Group Art Unit 1614	
PATENT & TRADEMARK OFFICE OCT 0 4 2002		Sansone, M. et al. Minaprine, but not Oxiracetam, Prevents Desipramine-Induced Impairment of Avoidance Learning in Mice. <i>Pol. J. Pharmacol.</i> 47, 69-73 (1995).			
BY		Sara, S.J. & Deweer, B. Memory Retrieval Enhanced by Amphetamine after a Long Retention Interval. <i>Behav. Neural Biol.</i> 36, 146-160 (1982).			
BZ		Soetens, E. et al. Amphetamine enhances human-memory consolidation. <i>Neurosci. Letters</i> 161, 9-12 (1993).			
CA		Soetens, E. et al. Effect of amphetamine on long-term retention of verbal material. <i>Psychopharmacology</i> 119, 155-162 (1995).			
CB		Strupp, B.J. et al. Time-Dependent Effects of Post-trial Amphetamine Treatment in Rats: Evidence for Enhanced Storage of Representational Memory. <i>Behavioral and Neural Biology</i> 56, 62-76 (1991).			
CC		Vree, T.B. & van Rossum, J.M. Kinetics of Metabolism and Excretion of Amphetamines in Man. <u>Amphetamines and Related Compounds</u> <i>Proceedings of the Mario Negri Institute for Pharmacological Res., Milan, Italy.</i> E. Costa & S. Garattini, eds. Raven Press, N.Y. 165-190 (1970).			
CD		Yi-Ping, H. & Lin, J.-S. Effects of modafinil and amphetamine on sleep-wake cycle after sleep deprivation in cats. <i>Acta. Pharmacol. Sin.</i> 20, 813-818 (Sept. 1999).			
CE		Zink, W.E. et al. Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse. <u>Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases</u> H. Friedman et al., eds. Kluwer Academic/Plenum Publishers 7-27 (2001).			
CF		Beckett, A.H. & Rowland, M. Urinary excretion kinetics of amphetamine in man. <i>J Pharm Pharmacol.</i> 17, 628-639 (Oct. 1965).			
CI		Jori, A. et al. Differences in the Availability of d-and l-Enantiomers after Administration of Racemic Amphetamine to Rats. <i>Xenobiotica</i> 8, 589-595 (1978).			
CJ		Alles, G. Comparative Physiological Actions of Optically Isomeric Phenylisopropylamines. <i>Univ. of CA. Publ. Pharmacol.</i> 1, 129-150 (1939).			
CK		Angrist, B. et al. Comparative Psychotomimetic Effects of Stereoisomers of Amphetamine. <i>Nature</i> 234, 152-153 (19 Nov. 1971).			
CL		Arnold, L.E. et al. Levoamphetamine vs Dextroamphetamine in Minimal Brain Dysfunction. <i>Arch. Gen. Psychiatry</i> 33, 292-301 (March 1976).			
CM		Arnold, L.E. et al. Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome. <i>Arch. Gen. Psychiatry</i> 27, 816-822 (Dec. 1972).			
CN		Axelrod, J. et al. Effect of Psychotropic Drugs on the Uptake of H3-Norepinephrine by Tissues. <i>Science</i> 133, 383-384 (10 Feb. 1961).			
		Brown, G.L. et al. Plasma Levels of d-Amphetamine in Hyperactive Children. <i>Psychopharmacology</i> 62, 133-140 (1979).			
		DeLuca, J. Cognitive Dysfunction After Aneurysm of the Anterior Communicating Artery. <i>J. Clin. Exp. Neuropsychology</i> 14, 924-934 (1992).			

Form PTO/SB/08		Docket Number (Optional) NIIN-P01-011		Application Number 10/003,740	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Epstein et al.		Group Art Unit 1614	
		Filing Date October 31, 2001			
		Goldstein, L.B. Effects of amphetamines and small related molecules on recovery after stroke in animals and man. <i>Neuropharmacology</i> 39, 852-859 (2000).			
CP		Hartmann, E. & Cravens, J. Sleep: Effects of d- and l-Amphetamine in Man and in Rat. <i>Psychopharmacology</i> 50, 171-175 (1976).			
CQ		McIntyre, H.B. et al. Computer Analyzed EEG in Amphetamine-Responsive Hyperactive Children. <i>Psychiatry Res.</i> 4, 189-197 (1981).			
CR		Myers, C.E. et al. Impaired Delay Eyeblink Classical Conditioning in Individuals with Anterograde Amnesia Resulting from Anterior Communicating Artery Aneurysm Rupture. <i>Behav. Neurosci.</i> 115, 560-570 (2001).			
CS		Parkes, J.D. & Fenton, G.W. Levo(-) amphetamine and dextro(+) amphetamine in the treatment of narcolepsy. <i>J. Neurology, Neurosurg., & Psychiatry</i> 36, 1076-1081 (1973).			
CT		Parkes, J.D. et al. Amphetamines in the treatment of Parkinson's disease. <i>J. Neurology, Neurosurg., & Psychiatry</i> 38, 232-237 (1975).			
CU		Prinzmetal, M. & Alles, G.A. The Central Nervous System Stimulant Effects of Dextro-Amphetamine Sulphate. In <i>Stimulant Effects of Dextro-Amphetamine Sulphate</i> 200, 665-673 (Nov. 1940).			
CV		Simpson, L.L. Blood Pressure and Heart Rate Responses Evoked by d- and l-Amphetamine in the Pithed Rat Preparation. <i>J. Pharmacol. Exp. Therapeutics</i> 193, 149-159 (1975).			
CW		Song, J.K. et al. Neuroradiologic Diagnosis and Treatment of Vasospasm. <i>Cerebral Aneurysms</i> 7, 819-835 (Nov. 1997).			
CX		Van Kammen, D.P. & Murphy, D.L. Attenuation of the Euphoriant and Activating Effects of d- and l-Amphetamine by Lithium Carbonate Treatment. <i>Psychopharmacologia</i> 44, 215-224 (1975).			
CY		Walker-Batson, D. et al. Amphetamine Paired with Physical Therapy Accelerates Motor Recovery After Stroke. <i>Stroke</i> 26, 2254-2259 (Dec. 1995).			
CZ		Wan, S.H. et al. Kinetics, salivary excretion of amphetamine isomers, and effect of urinary pH. <i>Clin. Pharmacol. Ther.</i> 23, 585-590 (May 1978).			
DA		Toxicology and Carcinogenesis Studies of dl-Amphetamine Sulfate (Cas No. 60-13-9) in F344/N Rate and B6C3F ₁ Mice (Feed Studies). <i>National Toxicology Program, Technical Report Series No. 387</i> NIH Publication No. 91-2842 (June 1991).			
EXAMINER 			DATE CONSIDERED 7-23-03		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.					

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED
OCT 07 2002
TECH CENTER 1600/2900